57,036 Shares in Intellia Therapeutics, Inc. $NTLA Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 57,036 shares of the company’s stock, valued at approximately $965,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new position in shares of Intellia Therapeutics in the 3rd quarter worth about $30,000. Advisory Services Network LLC bought a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at about $33,000. Headlands Technologies LLC bought a new stake in shares of Intellia Therapeutics during the 2nd quarter valued at about $26,000. Comerica Bank raised its stake in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after acquiring an additional 901 shares during the period. Finally, Danske Bank A S bought a new position in Intellia Therapeutics in the third quarter worth about $50,000. Institutional investors own 88.77% of the company’s stock.

Analysts Set New Price Targets

NTLA has been the subject of a number of research reports. Wedbush lifted their target price on Intellia Therapeutics from $12.00 to $17.00 and gave the company a “neutral” rating in a research note on Friday, July 10th. Citizens Jmp reiterated a “market outperform” rating and set a $30.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, August 25th. Canaccord Genuity Group reissued a “buy” rating and issued a $49.00 price target on shares of Intellia Therapeutics in a report on Tuesday, June 16th. Evercore upgraded Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price objective for the company in a research report on Friday, August 7th. Finally, New Street Research set a $25.00 price objective on Intellia Therapeutics in a research report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $21.15.

Intellia Therapeutics Stock Up 0.5%

Shares of NASDAQ:NTLA opened at $12.74 on Friday. The company’s 50-day moving average price is $12.94 and its 200 day moving average price is $13.40. The company has a market cap of $1.79 billion, a PE ratio of -3.79 and a beta of 1.82. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The firm had revenue of $7.66 million during the quarter, compared to analysts’ expectations of $12.98 million. During the same quarter in the prior year, the firm earned ($0.98) EPS. Intellia Therapeutics’s quarterly revenue was down 46.4% on a year-over-year basis. As a group, equities analysts anticipate that Intellia Therapeutics, Inc. will post -3.21 EPS for the current year.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael Dube sold 2,641 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the transaction, the chief accounting officer directly owned 66,886 shares of the company’s stock, valued at $1,122,347.08. This represents a 3.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP J III sold 4,677 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the sale, the executive vice president owned 156,286 shares in the company, valued at approximately $2,813,148. This represents a 2.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.50% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.